Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas B Norgard

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Clinical Pharmacokinetics|November 16, 2017
Obesity and Altered Aspirin PharmacologyNicholas B Norgard
Expert Opinion on Investigational Drugs|July 17, 2009
Cangrelor: a novel P2Y12 receptor antagonistNicholas B Norgard
The Annals of Pharmacotherapy|November 4, 2010
Rhabdomyolysis in a patient receiving high-dose simvastatin after the induction of therapeutic hypothermiaNatalie Dearing, Nicholas B Norgard
Current Heart Failure Reports|February 13, 2017
Towards Precision in HF PharmacotherapyNicholas B Norgard, Carolyn Hempel
Drug Metabolism Letters|March 7, 2017
Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and PharmacodynamicsNicholas B Norgard, Scott V Monte
Journal of Cardiac Failure|September 18, 2022
Right Here and Right Now: Time to Incorporate Measures of Right Ventricular Function When Assessing Left Heart Failure Clinical OutcomesAngel Lopez-Candales, Nicholas B Norgard
Therapeutic Advances in Chronic Disease|July 3, 2015
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal useNicholas B Norgard, James J DiNicolantonio
Future Cardiology|June 2, 2011
Future of personalized pharmacotherapy in chronic heart failure patientsNicholas B Norgard, Gina M Prescott
Vascular Health and Risk Management|November 10, 2009
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary interventionNicholas B Norgard, Mazen Abu-Fadel
Drug, Healthcare and Patient Safety|June 25, 2011
Profound thrombocytopenia after primary exposure to eptifibatideNicholas B Norgard, Brian T Badgley
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Clinical Pharmacokinetics|November 16, 2017
Obesity and Altered Aspirin PharmacologyNicholas B Norgard
Expert Opinion on Investigational Drugs|July 17, 2009
Cangrelor: a novel P2Y12 receptor antagonistNicholas B Norgard
The Annals of Pharmacotherapy|November 4, 2010
Rhabdomyolysis in a patient receiving high-dose simvastatin after the induction of therapeutic hypothermiaNatalie Dearing, Nicholas B Norgard
Current Heart Failure Reports|February 13, 2017
Towards Precision in HF PharmacotherapyNicholas B Norgard, Carolyn Hempel
Drug Metabolism Letters|March 7, 2017
Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and PharmacodynamicsNicholas B Norgard, Scott V Monte
Journal of Cardiac Failure|September 18, 2022
Right Here and Right Now: Time to Incorporate Measures of Right Ventricular Function When Assessing Left Heart Failure Clinical OutcomesAngel Lopez-Candales, Nicholas B Norgard
Therapeutic Advances in Chronic Disease|July 3, 2015
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal useNicholas B Norgard, James J DiNicolantonio
Future Cardiology|June 2, 2011
Future of personalized pharmacotherapy in chronic heart failure patientsNicholas B Norgard, Gina M Prescott
Vascular Health and Risk Management|November 10, 2009
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary interventionNicholas B Norgard, Mazen Abu-Fadel
Drug, Healthcare and Patient Safety|June 25, 2011
Profound thrombocytopenia after primary exposure to eptifibatideNicholas B Norgard, Brian T Badgley
Pageof 3